Polymed Biopharmaceuticals

Company Deals

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline

Fineline Cube Oct 28, 2025

PolyMed Biopharmaceuticals Co., Ltd., a Chinese‑based, internationally‑oriented biopharma innovator, announced the successful closure of its...

Company Deals

PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development

Fineline Cube Feb 18, 2025

PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...

Company Deals

Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline

Fineline Cube Nov 30, 2022

China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod